Literature
The complete bibliography of “UltraBiome HandBook” — the original scientific sources behind the reference numbers that appear in the chapters.
What is in the bibliography?
This appendix holds the book’s complete bibliography in one place: every scientific reference cited in any chapter of the volume. The `[12]`, `[325]` and other numbers in the body text point to the entries listed below — the numbering runs across the entire book, so the same `[N]` reference number always points to the same source. The vast majority of the listed publications appeared in peer-reviewed journals and are also findable in indexed databases (PubMed/NCBI, Crossref), from reputable professional publishers.
Why is there a summary under each entry?
Under each reference there is a 5–6 sentence synopsis. This is not the article’s official abstract but a short, plain-language summary presenting the study’s background, the method used, the main result, and its clinical or practical significance. Its purpose is to let the reader quickly decide whether the full publication is worth reading and whether it fits their own question or the patient’s situation. The summaries help you orient yourself even without direct access to the full text.
How to use it?
Under each entry you will find the “Cited in” line: clicking the chapter number shown there returns you to the part of the book where the source is cited. Within that chapter, clicking the `[N]` marker brings the reader here, to the bibliography — so you can move freely in both directions. Clicking the reference marked “Link” opens the publication on the publisher’s or NCBI’s site, where — if the article is freely accessible (open access) — the full text can also be read.
References
[6] Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012. Link
Conceptual review describing the human gut as a complex ecological community whose collective metabolic activities and host interactions influence physiology and disease susceptibility. The gut microbiota is highly diverse, varies between individuals, and fluctuates over time, particularly during disease and early development. The authors argue that an ecological framework — addressing diversity, stability, and resilience — is necessary for designing effective microbiota-targeted therapies. The paper provides a theoretical foundation for clinical microbiome modulation strategies.
[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link
Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.
[13] Sonnenburg JL, Gardner E. Microbiome tests: Ignore the hype. Science. 2016. Link
Sonnenburg and Gardner’s Science commentary cautions against the marketing hype around direct-to-consumer microbiome tests in 2016. They argue that while gut microbiota research is advancing rapidly, commercial 16S rRNA profiling cannot yet deliver clinically actionable personalised advice because reference ‘healthy’ microbiomes are not defined, longitudinal data are sparse, and causal links between taxa and outcomes are largely unproven. The authors emphasise inter-individual variability, methodological differences between platforms, and the gap between association and intervention evidence. They recommend that clinicians treat such reports with skepticism and call for regulatory oversight, standardised methodology, and longitudinal cohort studies before personalised microbiome diagnostics enter routine care.
[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link
Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.
[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link
Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.
[49] DeFilipp Z, Bloom PP, Torres Soto M et al. Drug-Resistant E. coli Bacteremia (the presence of bacteria in the bloodstream) Transmitted by Fecal Microbiota Transplant. N Engl J Med. 2019. Link
Case report of two patients in independent FMT clinical trials who developed ESBL-producing Escherichia coli bacteremia after the procedure; both cases were linked to the same stool donor by genomic sequencing, and one patient died. Highlights the risk of multidrug-resistant organism transmission via FMT and supports enhanced donor screening protocols. The report underpins regulatory updates requiring multidrug-resistant pathogen screening of all FMT donor material.
[53] Cryan JF, O’Riordan KJ, Cowan CSM et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019. Link
Review of free fatty acids (FFAs) — including dietary long- and medium-chain fatty acids and microbially produced short-chain fatty acids (SCFAs) — as ligands for free fatty acid receptors (FFARs), a group of G protein-coupled receptors linking metabolism and immunity. FFARs regulate inflammation, peptide hormone secretion, and host energy balance. The authors summarize FFAR pharmacology and its translational potential as a target for metabolic and inflammatory disease.
[57] Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013. Link
Mechanistic study in mice showing that the SCFA butyrate, produced by Clostridia fermentation of dietary fibre, induces differentiation of colonic regulatory T (Treg) cells. NMR-based metabolomics showed luminal SCFA concentrations positively correlated with colonic Treg numbers. Butyrate acted via histone deacetylase inhibition on Foxp3 locus regulation. Identifies butyrate as a microbial mediator of mucosal immune tolerance and supports butyrate-augmenting interventions in inflammatory bowel disease.
[58] Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Martens EC, Schloss PD. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019. Link
Two-week dietary intervention in 174 healthy young adults supplementing with resistant starch from potatoes (RPS), resistant starch from maize (RMS), inulin, or accessible corn-starch control. RPS produced the greatest increase in total SCFAs including butyrate. Most microbiomes responded to RPS with increased bifidobacteria, but responders with rising Ruminococcus bromii or Clostridium chartatabidum showed the highest butyrate concentrations. The study demonstrates substrate- and taxon-specific routes to butyrate enrichment, informing personalized prebiotic strategies.
[59] Thaiss CA, Zeevi D, Levy M et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. 2014. Link
Mechanistic study in mice and humans demonstrating that the gut microbiota exhibits diurnal oscillations driven by feeding rhythms, producing time-specific compositional and functional profiles. Disruption of host molecular clock components or jet lag caused aberrant microbiota oscillations and dysbiosis through impaired feeding rhythmicity. Jet-lag-induced dysbiosis in both species promoted glucose intolerance and obesity that were transferable by FMT to germ-free recipients. Identifies microbiota–host circadian cross-regulation as a metabolic disease mechanism.
[60] Benedict C, Vogel H, Jonas W et al. Gut microbiota and glucometabolic alterations in response to recurrent partial sleep deprivation in normal-weight young individuals. Mol Metab. 2016. Link
Randomized within-subject crossover study in 9 normal-weight men comparing two nights of partial sleep deprivation (PSD; 02:45–07:00) with two nights of normal sleep (22:30–07:00) under standardized in-lab meal and exercise conditions. Faecal samples were collected and oral glucose tolerance was tested. The study assessed whether short-term sleep loss alters gut microbiota composition and metabolic function, providing early human evidence linking sleep restriction to acute microbiota shifts and insulin resistance.
[62] Clarke SF, Murphy EF, O’Sullivan O et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014. Link
Cross-sectional 16S rRNA amplicon study comparing gut microbiota composition in professional rugby athletes with control groups matched for physical size, age and gender. Athletes showed higher microbial diversity and distinct community structure linked to both extreme exercise and accompanying dietary differences. Provides early evidence that elite-level exercise and diet jointly shape the gut microbiota, supporting downstream investigations into the exercise–diet–microbiome triad in metabolic and immune health.
[63] Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014. Link
Review of the bile acid–gut microbiome axis in health and disease, focusing on two major microbial pathways for bile salt degradation and the impact of bile acid composition on microbiota and host physiology. Bile acid pool size is now recognized as a function of microbial bile acid metabolism. Bile acids regulate the microbiome at the highest taxonomic levels and act as signalling hormones, with emerging evidence implicating them in liver carcinogenesis. The review frames bile acids as bidirectional mediators of host–microbiome crosstalk.
[64] Valles-Colomer M, Falony G, Darzi Y et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019. Link
Large-scale metagenomics study in the Flemish Gut Flora Project (n=1,054) with replication in independent datasets (total n=1,070) assessing correlations between microbiome features and host quality of life and depression. Butyrate-producing Faecalibacterium and Coprococcus were consistently associated with higher quality-of-life indicators, while Coprococcus and Dialister were depleted in depression independent of antidepressant use. The study provides population-scale evidence for a gut microbiota signature of mental health and depression.
[69] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019. Link
Reynolds and colleagues report a Lancet 2019 series of systematic reviews and meta-analyses on carbohydrate quality and human health, commissioned by WHO. Pooling observational and intervention data from 185 prospective studies and 58 trials with over 4,600 participants, they find that high dietary fiber intake (25–29 g/day) is associated with 15–30% reductions in all-cause and cardiovascular mortality, incidence of coronary heart disease, stroke, type 2 diabetes and colorectal cancer. Whole grains show similar protective associations. Low glycemic index/load contributes incrementally. The authors recommend increasing fiber intake to at least 25–29 g/day and prioritising whole grains as a population-level prevention strategy.
[71] Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. The role of butyrate on colonic function. Aliment Pharmacol Ther. 2008. Link
Narrative review summarizing the bioactivity of butyrate — a SCFA produced by colonic microbial fermentation of dietary fibre — and its mechanisms in human colonic function. Butyrate is the primary energy source for colonocytes and modulates inflammation, carcinogenesis, mucosal barrier integrity, oxidative stress, permeability, and satiety. The review consolidates evidence on butyrate as a central effector of colonic homeostasis and a target for dietary interventions in colonic disease.
[73] Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014. Link
Conceptual review proposing that the gut microbiota of a healthy Western person may itself be dysbiotic and predispose to disease. The asymmetric plasticity between the relatively stable human genome and the malleable gut microbiome creates opportunity for rapid mismatch. Western diets low in microbiota-accessible carbohydrates (MACs) select for altered microbial membership and function, with immune dysregulation linking these shifts to inflammation-based disease. The paper frames Western lifestyle as a driver of microbiome-mediated chronic disease.
[88] Deehan EC, Yang C, Perez-Muñoz ME et al. Precision Microbiome Modulation with Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host Microbe. 2020. Link
Dose-response trial in healthy adults with three type-IV resistant starches (RS4s) differing in crystalline and phosphate cross-linked structures. Distinct RS4 chemical structures induced divergent and highly specific microbiome shifts linked to directed increases in either propionate or butyrate production. The data demonstrate that fibre structure can be used to predictably shape microbial metabolic output, supporting precision-prebiotic strategies for targeted SCFA induction.
[91] Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019. Link
Review of microbiome-informed probiotic assessment, addressing gut colonization by probiotics, strain-level activity, interactions with the indigenous microbiome, safety, and host impact. Conflicting clinical results for many strains and formulations reflect heterogeneity in colonization, host response, and indication. The review proposes a precision-probiotic paradigm linking strains to physiological effects and validated medical indications.
[100] Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017. Link
Review framing the gastrointestinal tract as a complex microbial ecosystem in symbiotic co-evolution with the host. Beneficial bacteria produce nutrients, prevent enteric pathogen infection, and modulate normal immune responses. The review summarizes strategies for modifying the intestinal microbiota to achieve, restore, and maintain favourable ecological balance, including diet, prebiotics, probiotics, and FMT.
[120] Calder, P. C. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017. Link
Review of omega-6 and omega-3 fatty acid roles in inflammation. EPA and DHA from oily fish or fish-oil supplements partly inhibit leucocyte chemotaxis, adhesion molecule expression, leucocyte-endothelial interactions, and the production of arachidonic-acid-derived eicosanoids and pro-inflammatory cytokines. EPA-derived eicosanoids are typically less potent than those from arachidonic acid, and EPA/DHA give rise to anti-inflammatory and inflammation-resolving mediators (resolvins, protectins, maresins), supporting their use in inflammatory conditions.
[124] Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007. Link
Bacterial lipopolysaccharide (LPS) is identified as a triggering factor for insulin resistance, obesity and diabetes. Plasma LPS fluctuates with feeding/fasting and a 4-week high-fat diet chronically increased it 2-3-fold (“metabolic endotoxemia”) while increasing the proportion of LPS-containing gut microbiota. Inducing comparable metabolic endotoxemia in mice via continuous subcutaneous LPS infusion for 4 weeks reproduced the high-fat-diet phenotype: increased fasting glycaemia and insulinaemia, weight gain, adipose F4/80+ inflammation, and hepatic triglyceride accumulation.
[126] Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001. Link
Resistant starch (RS) and nonstarch polysaccharides (NSP), the major components of dietary fibre, are fermented by human colonic bacteria to short-chain fatty acids — primarily acetate, propionate and butyrate. SCFAs stimulate colonic blood flow and fluid/electrolyte uptake; butyrate is the preferred colonocyte substrate and supports a normal colonocyte phenotype. Fermentation of certain RS types preferentially favours butyrate production, providing a mechanistic basis for the colon-health benefits of fibre-rich diets.
[127] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012. Link
Intestinal bacteria carry a far larger repertoire of degradative enzymes than the human host, particularly carbohydrate-active enzymes. Dominant Bacteroidetes such as B. thetaiotaomicron carry hundreds of glycoside hydrolases and switch energy sources flexibly. However, specialised primary degraders in Firmicutes, Actinobacteria and Verrucomicrobia appear critical for initiating breakdown of plant cell walls, starch particles and mucin. The review highlights how prebiotics and other dietary carbohydrates exert health effects via the intricate diet-microbiota-metabolite relationship.
[133] Cotillard A, Kennedy SP, Kong LC et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013. Link
Diet-induced weight-loss and weight-stabilisation intervention in 38 obese and 11 overweight individuals showed that those with low microbial gene richness (40% of the cohort) had more pronounced dysmetabolism and low-grade inflammation. Dietary intervention improved gene richness and clinical phenotypes but was less effective for inflammation in lower-richness individuals. The findings establish gut microbial gene richness as a baseline biomarker that stratifies obese patients by metabolic risk and response to dietary intervention.
[134] Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiota in obese and lean twins. Nature. 2009. Link
Faecal microbial community analysis of adult female monozygotic and dizygotic twin pairs concordant for leanness or obesity (and their mothers) yielded 9,920 near-full-length 16S rRNA sequences plus 2.14 Gb of metagenomic data from 154 individuals. Family members share a gut microbiome, but each person’s specific bacterial lineage composition varies; co-variation was comparable between monozygotic and dizygotic twin pairs, indicating that shared environment plays a major role alongside host genotype in shaping the gut microbiome.
[141] David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014. Link
Short-term consumption of diets composed entirely of animal versus plant products produced dramatic, reproducible shifts in human gut microbial community structure that overwhelmed inter-individual differences. The animal-based diet increased bile-tolerant microbes (Alistipes, Bilophila, Bacteroides) and decreased plant-polysaccharide-fermenting Firmicutes (Roseburia, E. rectale, R. bromii), mirroring herbivore-vs-carnivore patterns. Bilophila wadsworthia bloomed on the animal-based diet, mechanistically linking dietary fat, bile acids and the outgrowth of microbes capable of triggering inflammatory bowel disease.
[143] Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012. Link
Review of mechanisms by which the gut microbiota influences host metabolism, with implications for obesity, cardiovascular disease and metabolic syndromes including type 2 diabetes. The microbiota modulates host metabolic pathways by improving energy yield from food and by altering dietary and host-derived compound bioactivity. Better mechanistic understanding will support the development of metabolic-disease treatments targeting the microbiota.
[148] Tap J, Furet JP, Bensaada M et al. Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults. Environ Microbiol. 2015. Link
A 6-week nutritional trial in 19 healthy adults supplemented daily diet with 10 or 40 g dietary fibre for 5 days followed by 15-day washouts. Faecal samples were profiled with 16S pyrosequencing, intestinal genotoxicity, metatranscriptomics and SCFA analysis. Short-term fibre changes did not affect all individuals equally but produced significant within-individual genus-level shifts. Higher baseline microbiota richness was associated with higher microbiota stability upon increased fibre intake, supporting richness as a determinant of dietary response.
[149] Ridaura VK, Faith JJ, Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013. Link
Faecal microbiota from adult female twin pairs discordant for obesity was transplanted into germ-free mice fed mouse chow and US-style diets. Increased body and fat mass and obesity-associated metabolic phenotypes were transmissible by both uncultured and cultured fecal communities. Cohousing obese-microbiota mice with lean-microbiota cage mates prevented obesity development, with rescue driven by invasion of specific Bacteroidetes from lean into obese microbiota. The effect was diet-dependent, revealing rapid, transmissible and modifiable diet-by-microbiota interactions in body composition.
[159] Chassaing B, Koren O, Goodrich JK et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015. Link
In wild-type mice, relatively low concentrations of two ubiquitous emulsifiers — carboxymethylcellulose (CMC) and polysorbate-80 (P80) — induced low-grade inflammation and obesity/metabolic syndrome, and promoted robust colitis in mice predisposed to it. The mucus-protective barrier and microbiota composition were disrupted. The findings implicate dietary emulsifiers, ubiquitous components of processed foods, in the post-mid-20th-century rise in inflammatory bowel disease and metabolic disorders.
[172] Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014. Link
Randomised single-blind cross-over trial in 30 IBS patients and 8 controls compared a low-FODMAP diet (<0.5 g/meal) with a typical Australian diet for 21 days each (>=21-day washout). Almost all food was provided. The low-FODMAP arm produced significantly greater reduction in IBS symptoms measured on 0-100 mm visual analogue scales, supporting the low-FODMAP diet as an effective intervention for symptom control in IBS compared with a standard Western diet.
[178] Sanz Y, De Palma G. Gut microbiota, diet and chronic metabolic diseases. In: Proceedings of the Nutrition Society. 2009. Link
Sanz and De Palma’s 2009 Proceedings of the Nutrition Society paper reviews how gut microbiota, diet and chronic metabolic diseases interact. They summarise evidence that obesity, type 2 diabetes and metabolic syndrome are accompanied by dysbiotic shifts (altered Firmicutes/Bacteroidetes ratio, decreased Akkermansia muciniphila, reduced microbial diversity), and that dietary patterns — Western, Mediterranean, plant-based — drive these shifts. Mechanisms include increased energy harvest, LPS-mediated low-grade inflammation, altered SCFA and bile-acid signalling, and modulation of gut-derived hormones (GLP-1, PYY). Probiotics, prebiotics and dietary fiber are positioned as microbiota-targeted interventions. The review predates but anticipates much of the next decade’s translational research.
[193] Zarrinpar A, Chaix A, Yooseph S, Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metab. 2014. Link
The gut microbiome exhibits daily cyclical compositional fluctuations driven by the feeding/fasting cycle. Diet-induced obesity dampens the daily feeding/fasting rhythm and diminishes microbiota cyclical fluctuations. Time-restricted feeding (TRF), in which feeding is consolidated to the nocturnal phase in mice, partially restores cyclical fluctuations and protects against obesity and metabolic disease. TRF preferentially affects bacteria known to influence host metabolism, linking feeding rhythm, microbiome dynamics, and metabolic outcomes.